id	a02ed7ff8546dcbb596c3de6f914121a
record_format	ojs
spelling	Publication http://purl.org/coar/version/c_970fb48d4fbd8a85 https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Colombiana de Neumología Asociación Colombiana de Neumología y Cirugía de Tórax application/pdf Revista Colombiana de Neumología - 2021 Romero, Santiago info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 Artículo de revista 1 33 http://purl.org/redcol/resource_type/ARTREF info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/openAccess https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/417 http://purl.org/coar/access_right/c_abf2 Text inmunosupresión. TNF Factor de necrosis tumoral artritis reumatoide etanercept Tuberculosis miliar Celis, Luis Gustavo Zuleta Quintero, Paola Gabriela Zannin Ferrero, Andreina Prieto, Carolina Polanía, María Daniela Español Biological agents are innovative medicines that prevent the progression of joint damage in patients with various autoinmune diseases, impacting on their functionality and quality of life. Etanercept (ETN) is the first anti tumor necrosis factor agent (anti - TNF) approved for the treatment of rheumatoid arthritis. Despite the obvious benefits of using biological drugs in the treatment of rheumatoid arthritis, it has been observed that their use is associated with the develpoment of multiple adverse effects, such as an increase in the number of infections, like the opportunistic and granulomatous infections and the development of tuberculosis. There are clinical trials that seem to indicate that the risk of developing tuberculosis is lower when using etanercept (ETN) vs infliximab (IFX), Adalimumab (ADA), in patients with rheumatoid arthritis compared to anti – TNF biological agents. TNF is an important cytokine in the inflammatory response, in the process of autoinmune diseases and in the development of infections, anti – TNF agents are recommended in patients with moderate to severe rheumatoid arthritis, however, they are at high risk of developing immunosuppressive diseases such as active tuberculosis, there is an increases risk of developing active tuberculosis with monoclonal antibodies to fusión proteins. The clinical case of a woman with a history of significant rheumatoid arthiris in management with etanercept and methotrexate is presented. She was diagnosed with paucibacilary miliary tuberculosis secondary to the use of TNF – alpha. Journal article Miliary tuberculosis etanercept rheumatoid arthritis tumor necrosis factor TNF immunosuppression 10.30789/rcneumologia.v33.n1.2021.417 2021-10-13T16:17:57Z https://doi.org/10.30789/rcneumologia.v33.n1.2021.417 https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/417/476 24 19 2021-10-13 0121-5426 2538-9513 2021-10-13T16:17:57Z
institution	ASOCIACION COLOMBIANA DE NEUMOLOGIA Y CIRUGIA DE TORAX
thumbnail	https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADENEUMOLOGIAYCIRUGIADETORAX/logo.png
country_str	Colombia
collection	Revista Colombiana de Neumología
description_eng	Biological agents are innovative medicines that prevent the progression of joint damage in patients with various autoinmune diseases, impacting on their functionality and quality of life. Etanercept (ETN) is the first anti tumor necrosis factor agent (anti - TNF) approved for the treatment of rheumatoid arthritis. Despite the obvious benefits of using biological drugs in the treatment of rheumatoid arthritis, it has been observed that their use is associated with the develpoment of multiple adverse effects, such as an increase in the number of infections, like the opportunistic and granulomatous infections and the development of tuberculosis. There are clinical trials that seem to indicate that the risk of developing tuberculosis is lower when using etanercept (ETN) vs infliximab (IFX), Adalimumab (ADA), in patients with rheumatoid arthritis compared to anti – TNF biological agents. TNF is an important cytokine in the inflammatory response, in the process of autoinmune diseases and in the development of infections, anti – TNF agents are recommended in patients with moderate to severe rheumatoid arthritis, however, they are at high risk of developing immunosuppressive diseases such as active tuberculosis, there is an increases risk of developing active tuberculosis with monoclonal antibodies to fusión proteins. The clinical case of a woman with a history of significant rheumatoid arthiris in management with etanercept and methotrexate is presented. She was diagnosed with paucibacilary miliary tuberculosis secondary to the use of TNF – alpha.
author	Romero, Santiago Celis, Luis Gustavo Zuleta Quintero, Paola Gabriela Zannin Ferrero, Andreina Prieto, Carolina Polanía, María Daniela
spellingShingle	Romero, Santiago Celis, Luis Gustavo Zuleta Quintero, Paola Gabriela Zannin Ferrero, Andreina Prieto, Carolina Polanía, María Daniela inmunosupresión. Factor de necrosis tumoral artritis reumatoide etanercept Tuberculosis miliar Miliary tuberculosis etanercept rheumatoid arthritis tumor necrosis factor immunosuppression
author_facet	Romero, Santiago Celis, Luis Gustavo Zuleta Quintero, Paola Gabriela Zannin Ferrero, Andreina Prieto, Carolina Polanía, María Daniela
topicspa_str_mv	inmunosupresión. Factor de necrosis tumoral artritis reumatoide etanercept Tuberculosis miliar
topic	inmunosupresión. Factor de necrosis tumoral artritis reumatoide etanercept Tuberculosis miliar Miliary tuberculosis etanercept rheumatoid arthritis tumor necrosis factor immunosuppression
topic_facet	inmunosupresión. Factor de necrosis tumoral artritis reumatoide etanercept Tuberculosis miliar Miliary tuberculosis etanercept rheumatoid arthritis tumor necrosis factor immunosuppression
citationvolume	33
citationissue	1
publisher	Asociación Colombiana de Neumología y Cirugía de Tórax
ispartofjournal	Revista Colombiana de Neumología
source	https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/417
language	Español
format	Article
rights	https://creativecommons.org/licenses/by-nc-sa/4.0/ Revista Colombiana de Neumología - 2021 info:eu-repo/semantics/openAccess http://purl.org/coar/access_right/c_abf2
type_driver	info:eu-repo/semantics/article
type_coar	http://purl.org/coar/resource_type/c_6501
type_version	info:eu-repo/semantics/publishedVersion
type_coarversion	http://purl.org/coar/version/c_970fb48d4fbd8a85
type_content	Text
publishDate	2021-10-13
date_accessioned	2021-10-13T16:17:57Z
date_available	2021-10-13T16:17:57Z
url	https://revistas.asoneumocito.org/index.php/rcneumologia/article/view/417
url_doi	https://doi.org/10.30789/rcneumologia.v33.n1.2021.417
issn	0121-5426
eissn	2538-9513
doi	10.30789/rcneumologia.v33.n1.2021.417
citationstartpage	19
citationendpage	24
url2_str_mv	https://revistas.asoneumocito.org/index.php/rcneumologia/article/download/417/476
_version_	1797159575256825856

Código QR

Estadísticas y Métricas Alternativas

Títulos similares